

Person with cancer—progesterone receptor assay results, code N

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Person with cancer—progesterone receptor assay results, code N

Identifying and definitional attributes

Metadata item type:	Data Element
Short name:	Progesterone receptor assay results
METEOR identifier:	291341
Registration status:	Health , Standard 13/06/2004
Definition:	The results of progesterone receptor assay at the time or diagnosis of the primary breast tumour, as represented by a code.
Data Element Concept:	Person with cancer—progesterone receptor assay results
Value Domain:	Progesterone receptor assay result code N

Value domain attributes

Representational attributes

Representation class:	Code	
Data type:	Number	
Format:	N	
Maximum character length:	1	
	Value	Meaning
Permissible values:	1	Test done, results positive (progesterone receptor positive)
	2	Test done, results negative (Progesterone receptor negative)
Supplementary values:	0	Test not done (test not ordered or not performed)
	8	Test done but results unknown
	9	Unknown

Data element attributes

Collection and usage attributes


Collection methods:	The Australian Cancer Network Working Party established to develop guidelines for the pathology reporting of breast cancer recommends that hormone receptor assays be performed on all cases of invasive breast carcinoma. The report should include: <ul style="list-style-type: none">the percentage of nuclei staining positive and the predominant staining intensity (low, medium, high), anda conclusion as to whether the assay is positive or negative.
----------------------------	--

Source and reference attributes

Origin: Royal College of Pathologists of Australasia
 Australian Cancer Network
 Commission on Cancer American College of Surgeons

Reference documents: Royal College of Pathologists of Australasia Manual of Use and Interpretation of Pathology Tests: Third Edition Sydney (2001)
 Australian Cancer Network Working Party The pathology reporting of breast cancer. A guide for pathologists, surgeons and radiologists Second Edition Sydney (2001)
 Commission on Cancer, Standards of the Commission on Cancer Registry Operations and Data Standards (ROADS) Volume II (1998)

Relational attributes

Related metadata references: Is re-engineered from  [Progesterone receptor assay status, version 1, DE, NHDD, NHIMG, Superseded 01/03/2005.pdf](#) (14.9 KB)
No registration status

Implementation in Data Set Specifications: [Cancer \(clinical\) DSS](#)
[Health](#), Superseded 07/12/2005
DSS specific information: Hormone receptor status is an important prognostic indicator for breast cancer.

[Cancer \(clinical\) DSS](#)
[Health](#), Superseded 06/03/2009
DSS specific information: Hormone receptor status is an important prognostic indicator for breast cancer.

[Cancer \(clinical\) DSS](#)
[Health](#), Superseded 22/12/2009
DSS specific information: Hormone receptor status is an important prognostic indicator for breast cancer.

[Cancer \(clinical\) DSS](#)
[Health](#), Superseded 07/12/2011
DSS specific information: Hormone receptor status is an important prognostic indicator for breast cancer.